A recent study suggests that people who stop using popular weight-loss injections like semaglutide or tirzepatide may regain shed pounds far faster than those who halt conventional diet and exercise regimens.
Published data in a major health publication shows that while obese individuals frequently drop a large proportion of their total mass while using the jabs, the mass is regained at an average rate of 0.8 kg per month once they quit.
"Users using such medications must be cognizant of the danger of fast weight regain when the therapy is stopped," cautioned lead investigator Dr. Susan Jebb.
This pace of regain implies a return to pre-treatment weight within about 18 months.
Comparing Therapies
The analysis, which looked at 37 of trials involving thousands of participants, compared the results of these new drugs with older methods.
The team emphasize that individuals who lose weight through lifestyle changes alone typically see a less rapid creep back—around 0.1 kg a month—after stopping.
Understanding the Rapid Regain
Experts believe the way of the injections explains the accelerated rebound.
These medications imitate a body's own chemical called GLP-1, which moderates feelings of fullness.
"Artificially providing GLP-1 concentrations far above than normal could lead to the body to produce less of its own natural hormone, and may also reduce responsiveness to its actions," said Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this hormone supplement means appetite is no longer kept in check, making binge eating a significant risk."
An Ongoing Condition?
Health authorities recommend the jabs for individuals with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
Many experts argue that, given the high risk of weight regain, the therapy might need to be long-term.
This opinion is supported by pharmaceutical companies, who note that the findings "underscore the persistent nature of obesity," comparing it to managing conditions like hypertension.
User Accounts
Users who have discontinued the medication report a intense resurgence of appetite.
"It was like something that goes on and you're instantly ravenous," recalled an individual.
This difficulty is exacerbated if users have not established lasting dietary or behavioural changes during therapy.
Growing Use
Figures indicate that a significant number of adults in the UK have tried weight-loss jabs in the past year, with interest remaining high.
- Adoption is higher among women than men.
- The 40s and 50s demographic shows the greatest usage rates.
- Many obtain the medications through private prescriptions rather than public health services.
Ultimately, clinicians stress that while GLP-1 drugs are effective tools for weight loss, they are not a standalone cure and maintained weight loss hinges on integrated lifestyle support.
